UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 
 
FORM 12b-25

SEC FILE NUMBER

000-52218

  NOTIFICATION OF LATE FILING

CUSIP NUMBER

68235A200

 

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-CEN Form N-CSR

 

  For Period Ended: September 30, 2023
     
  Transition Report on Form 10-K
       
  Transition Report on Form 20-F
       
  Transition Report on Form 11-K
       
  Transition Report on Form 10-Q

 

  For the Transition Period Ended:  

 

Read Instructions (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION

 

Theralink Technologies, Inc.
Full Name of Registrant
 
 
Former Name if Applicable
 
15000 W. 6th Ave., #400
Address of Principal Executive Office (Street and Number)
 
Golden, CO 80401
City, State and Zip Code

 

 

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

  (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

 

Theralink Technologies, Inc., a Nevada corporation (the “Company”), is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the year ended September 30, 2023 (the “Form 10-K”).

 

The Company could not complete the filing of its Annual Report on Form 10-K for the period ended September 30, 2023, due to a delay in obtaining and compiling information required to be included in the Company’s Form 10-K, which delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-K no later than the fifteenth calendar day following the prescribed due date.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

  Andrew Kucharchuk   (888)   585-4923
  (Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
  Yes ☒ No ☐
   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
  Yes ☐ No ☒
   
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 

 

Theralink Technologies, Inc.

 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 29, 2023   By: /s/ Andrew Kucharchuk
      Andrew Kucharchuk
      Chief Financial Officer

 

 

 


Theralink Technologies (CE) (USOTC:THER)
過去 株価チャート
から 11 2024 まで 12 2024 Theralink Technologies (CE)のチャートをもっと見るにはこちらをクリック
Theralink Technologies (CE) (USOTC:THER)
過去 株価チャート
から 12 2023 まで 12 2024 Theralink Technologies (CE)のチャートをもっと見るにはこちらをクリック